Consistent with the role of resolving CD200+ FLSs in mediating RA remission, a previous study also demonstrated that CD200-Fc, which can target proinflammatory cytokine expression in the joint without any obvious systemic immunosuppressive effects, is an effective therapeutic agent for CIA [72]. The gene discussed is CD200; the disease is rheumatoid arthritis.